| Drug Name: | Carbimazole (22232-54-8) |
|---|---|
| PubChem ID: | 31072 |
| SMILES: | CCOC(=O)N1C=CN(C1=S)C |
| InchiKey: | CFOYWRHIYXMDOT-UHFFFAOYSA-N |
| Therapeutic Category: | Antithyroid Agents, Hormone Antagonists, Hormones |
| Molecular Weight (dalton) | : | 186.236 |
| LogP | : | 1.56069 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 36.16 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Erythromycin (114-07-8) | Torsade De Pointes | Antagonistic | Intravenous erythromycin may cause QT prolongation and torsade de pointes. It is rare with oral erythromycin. Carbimazole is rapidly metabolised to thiamazole which is the active form of the drug. | Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category